Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Uveal Melanoma Prognostic Test Garners Coverage from Multiple Payors

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued a final local coverage determination for Castle Biosciences' DecisionDx-UM, a prognostic test for uveal melanoma.

The LCD extends coverage for the DecisionDx-UM test to assess metastatic risk for newly diagnosed uveal melanoma patients, as well as to guide surveillance and referral to medical oncology.

According to the company, national payor Aetna will now also cover the test, as well as 14 Blue Cross Blue Shield (BCBS) insurance plans in California, Florida, New Jersey, North Carolina, Michigan, Massachusetts, Washington, Oregon, Alabama, Arizona, Louisiana, Utah, Idaho, and Alaska. Castle CEO Derek Maetzold said in a statement that these recent coverage determinations will extend access to DecisionDx-UM to 57 million Medicare recipients and 58 million insurance beneficiaries under BCBS and Aetna commercial plans.

DecisionDx-UM has been validated in multiple studies, including an analysis involving more than 400 patients that showed DecisionDx-UM to be "clinically and statistically superior to all other prognostic factors in predicting metastatic risk, including clinical and pathologic factors, as well as chromosome 3 testing," Castle highlighted in a statement. The company has also published two clinical utility studies that showed its test had a significant impact on patient management.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.